While most Australians are familiar with the term depression, a lesser known variation of the mental illness, ‘treatment-resistant depression’ (TRD) is impacting one in three Australians living with depression. Those struggling with TRD, see a lack of improvement following trials of two or more antidepressants. This can be debilitating for those already struggling and reduces expectations of future treatment success.


Tony Stevenson, CEO Mental Illness Fellowship of Australia  speak’s with Dave on the the impact of long-term depression and how patients who suffer    with a Major Depressive Disorder can experience a depressed mood and/or loss of interest or pleasure in almost all activities. One-third of people living with Major Depressive Disorder experience Treatment Resistant Depression, where there is a lack of improvement in MDD symptoms following adequate trials of two or more antidepressants.

In a related development announced today, a milestone for the mental health community with the first advancement in treatment for major depressive disorder in over 30 years.

TGA approved nasal spray, SPRAVATO provides a treatment option that may offer some improvement of depression symptoms for adults living with TRD when taken with oral antidepressants.

ultra106.5fm is proudly supported by:

SPRAVATO® is the only approved antagonist of the N-methyl-D-aspartate (NMDA) glutamate receptor for treatment resistant depression in Australia.1,2 It is administered via a non-invasive nasal spray under specialist clinical supervision to ensure that the medication is correctly administered and the safety of the patient considered first